Orexigen Terminates Required Study for Diet Drug Contrave
New trial for drug expected to begin later this year with completion date of 2022
 Updated May 12, 2015 12:57 p.m. ET 
 
Orexigen Therapeutics said Tuesday it has terminated a required cardiovascular outcomes trial of its obesity drug Contrave, after prematurely releasing interim study results in March.
Shares, up 13% this year, fell 8% in midday trading. 
The company noted that the study isnâ€™t being terminated because of the finding of superiority or harm.... 
 To Read the Full Story
